[go: up one dir, main page]

EE03858B1 - Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine - Google Patents

Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine

Info

Publication number
EE03858B1
EE03858B1 EEP199900179A EE9900179A EE03858B1 EE 03858 B1 EE03858 B1 EE 03858B1 EE P199900179 A EEP199900179 A EE P199900179A EE 9900179 A EE9900179 A EE 9900179A EE 03858 B1 EE03858 B1 EE 03858B1
Authority
EE
Estonia
Prior art keywords
conjugates
preparation
pharmaceutical composition
prostate cancer
cancer drugs
Prior art date
Application number
EEP199900179A
Other languages
English (en)
Estonian (et)
Other versions
EE9900179A (et
Inventor
M. Garsky Victor
Feng Dong-Mei
Defeo-Jones Deborah
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900179A publication Critical patent/EE9900179A/xx
Publication of EE03858B1 publication Critical patent/EE03858B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP199900179A 1996-10-30 1997-10-27 Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine EE03858B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
EE9900179A EE9900179A (et) 1999-12-15
EE03858B1 true EE03858B1 (et) 2002-10-15

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900179A EE03858B1 (et) 1996-10-30 1997-10-27 Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine

Country Status (31)

Country Link
EP (1) EP0942754B1 (is)
JP (1) JP2000509407A (is)
KR (1) KR100508199B1 (is)
AR (1) AR008907A1 (is)
AT (1) ATE239509T1 (is)
AU (1) AU726434B2 (is)
BG (1) BG64768B1 (is)
BR (1) BR9712589A (is)
CA (1) CA2268738A1 (is)
CO (1) CO4930281A1 (is)
CZ (1) CZ155599A3 (is)
DE (1) DE69721810T2 (is)
DK (1) DK0942754T3 (is)
DZ (1) DZ2333A1 (is)
EA (1) EA002066B1 (is)
EE (1) EE03858B1 (is)
ES (1) ES2196374T3 (is)
HR (1) HRP970566A2 (is)
HU (1) HUP0000651A3 (is)
ID (1) ID21358A (is)
IL (1) IL129356A0 (is)
IS (1) IS5025A (is)
NO (1) NO992069L (is)
PE (1) PE17399A1 (is)
PL (1) PL333004A1 (is)
PT (1) PT942754E (is)
SK (1) SK57399A3 (is)
TR (1) TR199901485T2 (is)
TW (1) TW425286B (is)
WO (1) WO1998018493A2 (is)
YU (1) YU21399A (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1036093A1 (en) * 1997-12-02 2000-09-20 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
EP1098666B1 (en) * 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU773420B2 (en) * 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
US6552166B1 (en) 1999-10-19 2003-04-22 Merck & Co., Inc. Process for the preparation of conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
EP1228089A2 (en) * 1999-10-27 2002-08-07 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
KR20030009388A (ko) 2000-03-15 2003-01-29 브리스톨-마이어스 스퀴브 파마 컴파니 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도
AU2003217676B2 (en) * 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
US8518891B2 (en) * 2006-11-29 2013-08-27 Longqin Hu Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
US8642555B2 (en) 2009-03-09 2014-02-04 Ktb Tumorforschungsgesellschaft Mbh Prodrugs
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のt細胞エピトープを有する標的化部分ペプチドエピトープ複合体
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体

Also Published As

Publication number Publication date
ID21358A (id) 1999-05-27
BG64768B1 (bg) 2006-03-31
HUP0000651A3 (en) 2001-12-28
ES2196374T3 (es) 2003-12-16
HRP970566A2 (en) 1998-08-31
TW425286B (en) 2001-03-11
JP2000509407A (ja) 2000-07-25
TR199901485T2 (xx) 1999-08-23
IL129356A0 (en) 2000-02-17
EP0942754B1 (en) 2003-05-07
PT942754E (pt) 2003-08-29
KR100508199B1 (ko) 2005-08-17
EA199900428A1 (ru) 2000-02-28
EA002066B1 (ru) 2001-12-24
AR008907A1 (es) 2000-02-23
DE69721810T2 (de) 2004-03-11
ATE239509T1 (de) 2003-05-15
DZ2333A1 (fr) 2002-12-28
HUP0000651A2 (hu) 2000-06-28
PL333004A1 (en) 1999-11-08
CZ155599A3 (cs) 1999-10-13
AU726434B2 (en) 2000-11-09
KR20000052970A (ko) 2000-08-25
HK1024876A1 (en) 2000-10-27
IS5025A (is) 1999-04-13
BG103436A (en) 2000-04-28
WO1998018493A3 (en) 1998-07-23
EP0942754A2 (en) 1999-09-22
BR9712589A (pt) 1999-10-26
SK57399A3 (en) 2000-01-18
CA2268738A1 (en) 1998-05-07
WO1998018493A2 (en) 1998-05-07
AU5149798A (en) 1998-05-22
PE17399A1 (es) 1999-02-20
CO4930281A1 (es) 2000-06-27
EE9900179A (et) 1999-12-15
NO992069D0 (no) 1999-04-29
YU21399A (sh) 2000-03-21
DE69721810D1 (de) 2003-06-12
DK0942754T3 (da) 2003-08-04
NO992069L (no) 1999-06-30

Similar Documents

Publication Publication Date Title
EE03858B1 (et) Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine
EE200000723A (et) Asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
PL355433A1 (pl) Indolinony podstawione w pozycji 6, ich wytwarzanie oraz ich zastosowanie w kompozycjach farmaceutycznych
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
IL139286A0 (en) Polyol-ifn-beta conjugates, their preparation and use
DE69930033D1 (de) Wasserlösliches Hedgehog-Protein im ionischen Komplex und deren pharmazeutische Verwendung
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
PT911340E (pt) Isoquinolinas-3-carboxamidas substituidas, sua preparacao e utilizacao como farmacos
HUP0100507A3 (en) Polyethylene glycol-grf conjugates, site-specific preparation thereof, pharmaceutical compositions comprising thereof and their use
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
FI944600L (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
EE04954B1 (et) Peroraalselt v?i paikselt manustatav farmatseutiline preparaat ja selle ravimvorm
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
EE04317B1 (et) 4-okso-3,5-dihüdro-4H-püridasino[4.5-b]indool-1-etaanamiidi derivaadid, nende valmistamine ja kasutamine raviks
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
FI970740A7 (fi) Funktionaaliset terpyridiini-metallikompleksit, menetelmät niiden valmistamiseksi ja oligonukleotidikonjugaatit terpyridiini-metallikompleksien kanssa
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20041027